OC15. Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer

2008 ◽  
Vol 34 ◽  
pp. 12-13
Author(s):  
Matthew Winter ◽  
Helen Thorpe ◽  
Roger Burkinshaw ◽  
Samantha Beevers ◽  
Robert Coleman
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Neoadjuvant Chemotherapy ◽  
Primary Tumour ◽  
Tumour Response ◽  
Potential Influence

scholarly journals Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study

2013 ◽  
Vol 19 (10) ◽  
pp. 2755-2765 ◽  
Author(s):  
Matthew C. Winter ◽  
Caroline Wilson ◽  
Stuart P. Syddall ◽  
Simon S. Cross ◽  
Alyson Evans ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Pilot Study ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer

Predicting axillary response to neoadjuvant chemotherapy: the role of diffusion weighted imaging

2021 ◽  
Author(s):  
Lucia Graña-López ◽  
Tania Pérez-Ramos ◽  
Fiz Andrés Maciñeira ◽  
Ángeles Villares ◽  
Manuel Vázquez-Caruncho
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Diffusion Weighted Imaging ◽  
Primary Tumour ◽  
Pathologic Complete Response ◽  
Tumour Response ◽  
Complete Response ◽  
Adc Value ◽  
Diffusion Weighted ◽  
Adc Values ◽  
Response To Neoadjuvant Chemotherapy

Objective: The aim of this study is to investigate whether the primary tumour response to neoadjuvant chemotherapy (NAC), based on the increase in the ADC-values (apparent diffusion coefficient) within the breast lesion, could help to predict axillary complete response. Methods: We retrospectively included 74 patients who were treated with NAC followed by surgery at Lucus Augusti Hospital between January 2015 and September 2020. Simple logistic regression was used to evaluate the factors associated with axillary pathological complete response, including the changes in breast tumour ADC-values due to the treatment. Results: Axillary complete response was correlated with negative oestrogen receptor status, Her2 positivity and response of primary tumour. It was achieved in 31% of the patients. In addition, the increase in the tumour ADC-values with NAC was higher for responders. Among the tumours that demonstrated an increase in ADC-value >0.92 ×10−3 mm2/s, 42.8% (15/35) showed axillary complete response. Eight (20.5%) breast cancers with an increase in ADC below the cut-off value were found to have no metastatic nodes after treatment (p = 0.038). Conclusion: Our results suggest that the performance of models predicting axillary response to NAC can be improved by adding the tumour response determined also using diffusion-weighted imaging. Advances in knowledge: For the fist time, we investigate the relation between tumour response to NAC, assessed using diffusion-weighted imaging, and axillary pathologic complete response.

scholarly journals Mathematical Modelling of the Response of Breast Cancer to Drug Therapy

1997 ◽  
Vol 1 (2) ◽  
pp. 137-151 ◽  
Author(s):  
D. A. Cameron
Keyword(s):  
Breast Cancer ◽  
Mathematical Modelling ◽  
Response Curve ◽  
Growth Response ◽  
Tumour Growth ◽  
Primary Tumour ◽  
Regression Line ◽  
Tumour Response ◽  
Response To Chemotherapy ◽  
Cell Kill

mathematical modelling of tumour response in breast cancer offers the potential for further understanding of the mechanisms involved in a tumour's imperfect response to chemotherapy. Three different models of assessing response are studied; the simplest consisting of fitting a regression line to the logarithm of the tumour volumes; a study using exponential growth and an S-shaped growth response curve; and one that assumes log cell-kill and the possibilitu of primary tumour resistance to therapy. All thre can explain some facets of tumour biology, but it is the introduction of the possibility of resistance that appears to result in correlations with clinical outcome. The issue of Gompertz growth is discussed, since it is considered, although not without controversy, to best describe not only xenograft but also clinical tumour growth, and yet has not been used in any of the three models discussed. It appears that much of the data used to clinically validate Gompertz growth is before the period of maximum deceleratin, and thus the true relevance of this function to clinical tumour growth remains uncertain.

Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer

2017 ◽  
Vol 220 ◽  
pp. 46-51 ◽  
Author(s):  
Takashi Ishikawa ◽  
Kouhei Akazawa ◽  
Yoshie Hasegawa ◽  
Hirokazu Tanino ◽  
Jun Horiguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Neoadjuvant Chemotherapy ◽  
Survival Outcomes

scholarly journals Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy

2011 ◽  
Vol 369 (1955) ◽  
pp. 4512-4530 ◽  
Author(s):  
Albert E. Cerussi ◽  
Vaya W. Tanamai ◽  
David Hsiang ◽  
John Butler ◽  
Rita S. Mehta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Tumour Response ◽  
Spectroscopic Imaging ◽  
Complete Response ◽  
Pathological Response ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Pilot Studies

Diffuse optical spectroscopic imaging (DOSI) non-invasively and quantitatively measures tissue haemoglobin, water and lipid. Pilot studies in small groups of patients demonstrate that DOSI may be useful for longitudinal monitoring and predicting breast cancer neoadjuvant chemotherapy pathological response. This study evaluates the performance of a bedside DOSI platform in 34 breast cancer patients followed for several months. DOSI optical endpoints obtained at multiple timepoints are compared with final pathological response. Thirty-six stage II/III breast cancers (34 patients) were measured in vivo with DOSI prior to, in the middle of and after the completion of pre-surgical neoadjuvant chemotherapy. Cancer therapies ranged from standard anthracyclines to targeted therapies. Changes in DOSI-measured parameters at each timepoint were compared against final surgical pathology. Absolute changes in the tumour-to-normal (T/N) ratio of tissue deoxyhaemoglobin concentration (ctHHb) and relative changes in the T/N ratio of a tissue optical index (TOI) were most sensitive and correlate to pathological response. Changes in ctHHb and TOI were significantly different between tumours that achieved pathological complete response (pCR) versus non-pCR. By therapy midpoint, mean TOI-T/N changes were 47±8 versus 20±5 per cent for pCR versus non-pCR subjects, respectively ( Z =0.011). Changes in ctHHb and TOI scaled significantly with the degree of pathological response (non-, partial and complete). DOSI measurements of TOI separated pCR from non-pCR by therapy midpoint regardless of drug or dosing strategy. This approach is well suited to monitoring breast tumour response and may provide feedback for optimizing therapeutic outcomes and minimizing side-effects.

Sign in / Sign up

Export Citation Format

Share Document